Intra-Cellular Therapies, Inc.
http://www.intracellulartherapies.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Intra-Cellular Therapies, Inc.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Otsuka Counts The Cost Of Alzheimer’s Agitation Fail
The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.
Reviva’s First Phase III Schizophrenia Readout Rivals Karuna’s Stellar KarXT
Small cap biopharma firm Reviva Pharmaceuticals reported intriguing Phase III results for its schizophrenia candidate brilaroxazine that are at least on par with Karuna’s closely watched drug.
Schizophrenia, Depression And Neuropathy: What’s Coming In 2024
The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice